The biotech industry is experiencing a dilemma related to digital twins, which are being used to rewrite clinical trial math. However, a validation problem may undermine the potential gains of this approach. The use of digital twins in clinical trials is also being explored in the rare disease community, where it may be reimagining the traditional clinical trial model.